HPV vaccine uptake after introduction of the vaccine in Germany

Hense, Sabrina; Hillebrand, Kathrin; Horn, Johannes; Mikolajczyk, Rafael; Schulze‐Rath, Renate; Garbe, Edeltraut

doi:10.4161/hv.28450

Cited by 13 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hense et al evaluated initiation of HPV vaccination in 2008 based on data from a statutory health insurance and reported 37% of 16 years old girls with at least one dose, which would overlap with birth cohort 1992. In the same publication rates were 33, 19 and 18% for 17-, 18-, and 19-year-old women, respectively (corresponding to birth cohorts 1992-1989) [19]. Delere et al reported HPV vaccination coverage based on self-reported history of approximately 2000 women aged between 18 and 20 years old in 2010 (cohorts 1990-1992) with 48.5% for three doses and 60.2% for at least one dose [24].…”

Section: Discussionmentioning

confidence: 96%

“…It may be speculated that a vaccine effect might be masked in an analysis without selection for vaccine-HPV type-associated disease. And 3), also for birth cohort 1989, which was not entirely eligible for HPV vaccination according to STIKO recommendation, a coverage of approximately 18% was reported in 2008 [19]. This birth cohort turned 18 during the year 2007 and thus girls may have had the chance to receive the vaccination regularly before their birthday.…”

Section: Discussionmentioning

confidence: 99%

“…Since 2018, HPV vaccination is recommended for girls and boys at the age of 9-14 with catch-up until the age of 17 [17]. In the first year after the introduction of the HPV vaccination in Germany (2008), the vaccination rate was reported with 32.2% for at least one dose in the target age group of the first STIKO recommendation (12-to 17-year-old girls) [18,19]. In 2015, the HPV vaccination rate was 31.3% in 15 year old and 44.6% in 17 year old girls (3 doses) [20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017

et al. 2020

View full text Add to dashboard Cite

Background: Most individuals are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data. Methods: We conducted a retrospective claims data analysis using the "Institute for Applied Health Research Berlin" (InGef) Research Database, containing claims data from approximately 4 million individuals. In the period from 2012 to 2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For catch-up vaccinations at the age of 15-17 years, the STIKO continued to recommend three doses. Since 2018, HPV vaccination is recommended for girls and boys at the age of 9-14 with catch-up until the age of 17 [17] In the first year after the introduction of the HPV vaccination in Germany (2008), the vaccination rate was reported with 32.2% for at least one dose in the target age group of the first STIKO recommendation (12-to 17-year-old girls) [18,19]. In 2015, the HPV vaccination rate was 31.3% in 15 year old and 44.6% in 17 year old girls (3 doses) [20].…”

Section: Introductionmentioning

confidence: 99%

Burden of HPV Related Anogenital Diseases in Young Women in Germany – An Analysis of German Statutory Health Insurance Claims Data From 2012–2017

Reuschenbach

Mihm

Wölle

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Most women and men are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.Methods We conducted a retrospective claims data analysis using the “Institute for Applied Health Research Berlin” (InGef) Research Database, containing claims data from approximately 4 million insured individuals. In the period from 2012-2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).Results From 2012-2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable.Conclusions A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.

show abstract

“…Since the latest STIKO recommendation from 2018, HPV vaccination is recommended for girls and boys at the age of 9-14 with catch-up until the age of 17 [19]. In the first year after the introduction of the HPV vaccination in Germany (2008), the vaccination rate was reported with 32.2% for at least one dose in the target age group of the first STIKO recommendation (12-to 17-year-old girls) [20,21]. In 2015, the HPV vaccination rate was 31.3% in 15 year old and 44.6% in 17 year old girls (3 doses) [22].…”

Section: Introductionmentioning

confidence: 99%

Burden of HPV Related Anogenital Diseases in Young Women in Germany – An Analysis of German Statutory Health Insurance Claims Data From 2012–2017

Reuschenbach¹,

Mihm

Wölle

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Most women and men are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.MethodsWe conducted a retrospective claims data analysis using the “Institute for Applied Health Research Berlin” (InGef) research database, containing claims data from approximately 4 million insured individuals. In the period from 2012-2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).ResultsFrom 2012-2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable. Conclusions A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.

show abstract

HPV vaccine uptake after introduction of the vaccine in Germany

Cited by 13 publications

References 28 publications

Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017

Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017

Burden of HPV Related Anogenital Diseases in Young Women in Germany – An Analysis of German Statutory Health Insurance Claims Data From 2012–2017

Burden of HPV Related Anogenital Diseases in Young Women in Germany – An Analysis of German Statutory Health Insurance Claims Data From 2012–2017

Contact Info

Product

Resources

About